After listening to the last webcast the other day it is pleasing to hear not of their technology but the roll out of their hvad, increasing implant centre numbers and their responses to criticism regarding strokes associated to the device.
Of particular interest to me was the indication he gave relating to the determination by physicians on whether the device implantation will be either BTT or DT and the fact that now their device has been approved many teams have indicated that they will opt for Heartwares device as BTT instead of Thoratecs as DT which is where the big growth will ultimately come from. l guess once the implant is done as BTT it can stay there effectively as DT by default. This hopefully will be reflected in their sales reports in future.
Roughly speaking if they increase to 2000 per annum they will be in the black which is not far off.
All the best to holders as 2013 should be a good year and have a great Christmas to all.
HIN Price at posting:
$2.20 Sentiment: LT Buy Disclosure: Held
